We are live on ! Find out more
IVM

InterWest Venture Management Portfolio holdings

AUM $20.6M
1-Year Est. Return 48.5%
This Fund
S&P 500
This Quarter Est. Return
-30.69%
1 Year Est. Return
+48.5%
3 Year Est. Return
-57.65%
5 Year Est. Return
-76.52%
10 Year Est. Return
–
AUM
$380M
AUM Growth
-$420M
Cap. Flow
-$158M
Cap. Flow %
-41.57%
Top 10 Hldgs %
99.94%
Holding
13
New
–
Increased
–
Reduced
5
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
AI icon
C3.ai
AI
+$40.3M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$39.4M
3
REAL icon
The RealReal
REAL
+$36.9M
4
GKOS icon
Glaukos
GKOS
+$26.4M
5
STIM icon
Neuronetics
STIM
+$7.62M

Sector Composition

Rank Sector Weight
1 Healthcare 61.94%
2 Technology 24.04%
3 Consumer Discretionary 14.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PMVP icon
1
PMV Pharmaceuticals
PMVP
$62.9M
$180M 47.32%
5,469,911
-1,000,000
-15% -$39.4M
AI icon
2
C3.ai
AI
$1.37B
$91.4M 24.04%
1,386,774
-346,693
-20% -$40.3M
REAL icon
3
The RealReal
REAL
$1.4B
$53.3M 14.01%
2,354,080
-1,500,000
-39% -$36.9M
GKOS icon
4
Glaukos
GKOS
$8.92B
$29.1M 7.65%
346,364
-300,000
-46% -$26.4M
AGTC
5
DELISTED
Applied Genetic Technologies Corporation
AGTC
$7.12M 1.87%
1,404,515
– –
EIGR
6
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$6.77M 1.78%
25,497
– –
STIM icon
7
Neuronetics
STIM
$126M
$6.15M 1.62%
497,158
-497,157
-50% -$7.62M
CDTX
8
DELISTED
Cidara Therapeutics
CDTX
$3.61M 0.95%
67,841
– –
VERO
9
DELISTED
Venus Concept
VERO
$1.55M 0.41%
3,992
– –
HIND
10
Vyome Holdings
HIND
$14M
– –
0
– –
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.36B
$148K 0.04%
8,293
– –
DARE icon
12
Dare Bioscience
DARE
$19.8M
$85K 0.02%
4,197
– –
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
– –
-388,766
Closed -$7.38M

Similar funds

RCP
Rho Capital Partners New York $20.4M AUM
LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

InterWest Venture Management's Q1 2021 Portfolio in Review

As of Q1 2021, InterWest Venture Management held 13 positions worth $380M, down 53% from $801M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

InterWest Venture Management withdrew a net $158M in Q1 2021, closing 1 position and reducing 5 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $7.38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, up from 61% a quarter earlier, followed by Technology and Consumer Discretionary.

  • InterWest Venture Management's biggest Q1 2021 reduction was C3.ai, cutting an estimated $40.3M.
  • InterWest Venture Management fully exited KalVista Pharmaceuticals in Q1 2021, selling an estimated $7.38M.
  • InterWest Venture Management's ten largest holdings make up 100% of its $380M portfolio in Q1 2021.
  • InterWest Venture Management opened 0 new positions and closed 1 in Q1 2021.
  • InterWest Venture Management's portfolio value fell 53% quarter-over-quarter to $380M.

Based on InterWest Venture Management's 13F filing for Q1 2021, filed 15 Apr 2021.